Home›Drug Pipeline› Palmitoylethanolamide and Adelmidrol show promise as adjunctive pediatric therapies
Palmitoylethanolamide and Adelmidrol show promise as adjunctive pediatric therapiesNew options for managing chronic symptoms in children with respiratory issues
Frontiers in MedicinePublished September 17, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret palmitoylethanolamide and Adelmidrol findings cautiously; effect sizes and comparators were not reported.
This is a narrative review of oral palmitoylethanolamide (mostly micron-sized formulations), topical palmitoylethanolamide, and topical Adelmidrol in pediatric patients. The review covers 2,530 patients, of whom 1,772 received palmitoylethanolamide and 54 received Adelmidrol. The authors synthesize literature across behavioral, cognitive, motor, and visceral functions as well as respiratory and dermatological disorders.
The review reports beneficial effects on behavioral, cognitive, motor, and visceral functions, and improvements in respiratory and dermatological disorders. No effect sizes, absolute numbers, p-values, or confidence intervals were reported for any outcome. The comparator, primary outcome, follow-up duration, and setting were not reported.
Safety data were limited. Adverse events, serious adverse events, and discontinuations were not reported. The agents were described as well-tolerated. The review did not report limitations, funding, or conflicts of interest.
The authors position these agents as potential promising, well-tolerated adjunctive strategies for managing pediatric symptoms, particularly in chronic conditions or those requiring polypharmacy. Because this is a narrative review without reported effect sizes or comparator data, the findings should be interpreted as hypothesis-generating rather than practice-changing. Clinicians should note that specific clinical trial data for individual outcomes are not detailed in the abstract.
How this fits prior evidence
This narrative review extends prior coverage of adjunctive and diagnostic strategies in pediatric care by shifting focus to palmitoylethanolamide and Adelmidrol across respiratory, dermatological, and functional domains. Unlike the prior systematic review of AI diagnostic tools, which reported accuracy above 90% but limited real-world validation, this review reports beneficial effects without effect sizes, comparators, or follow-up. Both sources share a common limitation: findings are drawn from selected literature and require cautious interpretation before clinical adoption.
Managing chronic conditions in children can be a long road for families. When a child deals with persistent respiratory issues or skin problems, the goal is to find treatments that work well and are easy for the child to tolerate. Recent reviews of the data suggest that two specific options, palmitoylethanolamide and Adelmidrol, show promise in these areas.
Researchers looked at data from over 2,500 patients. They found that palmitoylethanolamide, which can be taken as a pill or a cream, showed improvements in respiratory and skin conditions. It also appeared to help with a child's behavior, thinking, and physical movements. Adelmidrol, used on the skin, also showed positive results for skin issues.
While these options are described as well-tolerated, it is important to remember that the evidence is still early. The data shows these treatments are promising additions to a child's care plan, especially for those with long-term conditions. Always talk to your doctor to see if these specific options fit your child's unique needs.
What this means for you:
Palmitoylethanolamide and Adelmidrol show promise for managing respiratory and skin issues in children.
Common questions
What are the benefits for children with respiratory issues?
The review found that palmitoylethanolamide showed improvements in respiratory disorders. It was also noted to have beneficial effects on a child's behavior, cognitive functions, and motor functions. These findings suggest it could be a helpful addition for children with chronic conditions.
Is the treatment safe for children?
The study reported that these treatments were well-tolerated in the patients reviewed. While specific side effects were not detailed in the summary, the findings suggest they are promising options for managing symptoms in children who require ongoing care.
How is the treatment for skin conditions administered?
For skin issues, the review looked at both palmitoylethanolamide, which can be used in topical forms, and Adelmidrol, which is applied topically. Both showed improvements for dermatological disorders in the patients studied.
IntroductionAlthough most children require medications only for occasional acute conditions, a significant proportion lives with chronic diseases that necessitate long-term, often multiple treatments, which negatively impact their health and quality of life, and may lead to adverse outcomes. Challenges related to prescribing and formulation further complicate pediatric treatment, underscoring the need for safe and effective innovative strategies. Autacoid Local Injury Antagonism amides (ALIAmides), particularly palmitoylethanolamide (PEA) and Adelmidrol, represent promising therapeutic options. This structured narrative review aims to collect and discuss all available literature on PEA and Adelmidrol use in pediatric patients.MethodsA search of PubMed, Scopus, and the Cochrane Library identified 17 studies involving a total of 2,530 patients, of whom 1,772 received PEA (oral or topical), and 54 received Adelmidrol. Following a transdiagnostic approach, results were organized by symptom domains rather than by specific diagnoses, to capture potential benefits across multiple conditions and facilitate comparison with previous studies. Data extraction included study design, population characteristics, intervention type and formulation, outcomes assessed, and main findings.ResultsBeneficial effects on behavioral, cognitive, motor, and visceral functions, along with improvements in respiratory and dermatological disorders emerged from studies administering oral PEA, mostly in micron-sized formulations. Topical application of both PEA and Adelmidrol also demonstrated benefits on respiratory and skin conditions.ConclusionOverall, the findings of this review suggest that PEA and Adelmidrol may represent promising, well-tolerated adjunctive strategies for managing pediatric symptoms across various clinical conditions, particularly those that are chronic or require polypharmacy.
